Ovarian hyperstimulation syndrome is correlated with a reduction of soluble VEGF receptor protein level and a higher amount of VEGF-A

Human Reproduction

Volumn 27, Issue 1, 2012, Pages 196-199

  Pietrowski, D ^a,b   Szabo, L ^a   Sator, M ^a,b   Just, A ^a,b   Egarter, C ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Fertility Center Dbling   (Austria)

Author keywords

angiogenesis; assisted reproduction; follicle development; ovarian hyperstimulation syndrome; vascular endothelial growth factor

Indexed keywords

RECOMBINANT CHORIONIC GONADOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FERTILIZATION IN VITRO; HUMAN; INFERTILITY; OVARY HYPERSTIMULATION; PROTEIN BLOOD LEVEL; SINGLE DRUG DOSE;

EID: 83755220518     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/der349     Document Type: Article

References (26)

1. Agrawal R, Tan SL, Wild S, Sladkevicius P, Engmann L, Payne N, Bekir J, Campbell S, Conway G, Jacobs H. Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertil Steril 1999;71:287-293. (Pubitemid 29069906)
2. Bates DO, Harper SJ. Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol 2002;39:225-237. (Pubitemid 37490748)
3. Becker J, Pavlakovic H, Ludewig F, Wilting F, Weich HA, Albuquerque R, Ambati J, Wilting J. Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2. Clin Cancer Res 2010;16:1431-1441.
4. Chen CD, Chen HF, Lu HF, Chen SU, Ho HN, Yang YS. Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome. Hum Reprod 2000; 15:1037-1042.
5. De Leener A, Montanelli L, Van Durme J, Chae H, Smits G, Vassart G, Costagliola S. Presence and absence of follicle-stimulating hormone receptor mutations provide some insights into spontaneous ovarian hyperstimulation syndrome physiopathology. J Clin Endocrinol Metab 2006;91:555-562. (Pubitemid 43236926)
6. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002;8:559-577. (Pubitemid 35452781)
7. Enskog A, Nilsson L, Brännström M. Plasma levels of free vascular endothelial growth factor(165) (VEGF(165)) are not elevated during gonadotropin stimulation in in vitro fertilization (IVF) patients developing ovarian hyperstimulation syndrome (OHSS): results of a prospective cohort study with matched controls. Eur J Obstet Gynecol Reprod Biol 2001;96:196-201. (Pubitemid 32522560)
8. Eriksson U, Alitalo K. Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr Top Microbiol Immunol 1999;237:41-57. (Pubitemid 28554858)
9. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999;77:527-543. (Pubitemid 29426311)
10. Gagné D, Pagé M, Robitaille G, Hugo P, Gosselin D. Levels of vascular endothelial growth factor (VEGF) in serum of patients with endometriosis. Hum Reprod 2003;18:1674-1680. (Pubitemid 36958049)
11. Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989;44:430-440. (Pubitemid 19138981)
12. Gómez R, Simón C, Remohí J, Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology 2002;143:4339-4348. (Pubitemid 35239566)
13. Jaroszewicz J, Januszkiewicz M, Flisiak R, Rogalska M, Kalinowska A, Wierzbicka I. Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: possible association with hepatic function impairment. Cytokine 2008;44:14-17.
14. Kobayashi H, Okada Y, Asahina T, Gotoh J, Terao T. The kallikrein-kinin system, but not vascular endothelial growth factor, plays a role in the increased vascular permeability associated with ovarian hyperstimulation syndrome. J Mol Endocrinol 1998;20:363-374. (Pubitemid 28277525)
15. Koos RD. Increased expression of vascular endothelial growth/permeability factor in the rat ovary following an ovulatory gonadotropin stimulus: potential roles in follicle rupture. Biol Reprod 1995;52:1426-1435.
16. Kuemmel S, Thomas A, Landt S, Fuger A, Schmid P, Kriner M, Blohmer JU, Sehouli J, Schaller G, Lichtenegger W et al. Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer. Anticancer Res 2009;29:641-645.
17. Matalliotakis IM, Goumenou AG, Koumantakis GE, Neonaki MA, Koumantakis EE, Dionyssopoulou E, Athanassakis I, Vassiliadis S. Serum concentrations of growth factors in women with and without endometriosis: the action of anti-endometriosis medicines. Int Immunopharmacol 2003;3:81-89. (Pubitemid 36106453)
18. Mouawad R, Spano JP, Comperat E, Capron F, Khayat D. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. Eur J Cancer 2009;45:1407-1414. Epub 20 Jan 2009.
19. Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 2008;11:109-119.
20. Neulen J, Raczek S, Pogorzelski M, Grunwald K, Yeo TK, Dvorak HF, Weich HA, Breckwoldt M. Secretion of vascular endothelial growth factor/vascular permeability factor from human luteinized granulosa cells is human chorionic gonadotrophin dependent. Mol Hum Reprod 1998;4:203-206. (Pubitemid 28172585)
21. Ni XF, Wu CP, Jiang JT. Serum VEGFR-3 and survival of advanced gastric cancer patients treated with FOLFOX. World J Gastroenterol 2010; 16:2163-2169.
22. Pau E, Alonso-Muriel I, Gómez R, Novella E, Ruiz A, García-Velasco JA, Simón C, Pellicer A. Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome. Hum Reprod 2006;21:1453-1460. (Pubitemid 44445021)
23. Rodewald M, Herr D, Duncan WC, Fraser HM, Hack G, Konrad R, Gagsteiger F, Kreienberg R, Wulff C. Molecular mechanisms of ovarian hyperstimulation syndrome: paracrine reduction of endothelial claudin 5 by hCG in vitro is associated with increased endothelial permeability. Hum Reprod 2009;24:1191-1199.
24. Soares SR, Gómez R, Simón C, García-Velasco JA, Pellicer A. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update 2008;14: 321-333. (Pubitemid 351858972)
25. Walz A, Keck C, Weber H, Kissel C, Pietrowski D. Effects of luteinizing hormone and human chorionic gonadotropin on corpus luteum cells in a spheroid cell culture system. Mol Reprod Dev 2005;72: 98-104. (Pubitemid 41026311)
26. Wang TH, Horng SG, Chang CL, Wu HM, Tsai YJ, Wang HS, Soong YK. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J Clin Endocrinol Metab 2002;87:3300-3308.